Jan 20, 2021
RAND Europe was commissioned by Wellcome to analyse the role and contribution of the Wellcome Sanger Institute and the Wellcome Genome Campus within the field of genetics and genomics. The study also looked at four comparator organisations—the Broad Institute, Wellcome Centre for Human Genetics, Janelia Research Campus and the National Human Genome Research Institute. The methods for this study consisted of desk research, case studies, interviews and bibliometric analysis.
Our review found that the main strengths of the Sanger Institute and Genome Campus centre around their leadership and convening role in many international research collaborations, which is also a strength for other large research institutes such as the Broad Institute. The Sanger Institute prioritises openness in sharing data and tools and publishing research, which helps them achieve impact from their work. However, this approach has meant that commercialisation of research has not been as strong as compared to other organisations. The field of genetics and genomics is advancing rapidly, particularly due to availability and affordability of high throughput sequencing technologies, which has changed the competitive advantage that such technologies offer to organisations. The next challenge will be to find a direction for these organisations to explore that fits with their scale, operating environments, unique strengths and values. In the case of Sanger, this means finding an approach that capitalises on their ethos of openness, data sharing and collaboration to shape the development of the field over the coming years.
Review of Wellcome Sanger Institute and Wellcome Genome Campus
Case study structure